Nuvectis Pharma Gets FDA Nod For Initial-Stage Ovarian Cancer Study

The U.S. Food and Drug Administration (FDA) cleared Nuvectis Pharma’s (NASDAQ:NVCT) Investigational New Drug Application (IND) for NXP800, which includes the Phase 1 clinical trial protocol.

The NXP800 Phase 1 clinical trial is comprised of two parts, a Phase 1a dose escalation study to be followed by the Phase 1b expansion study.